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ell Therapy for Heart Disease
here Are We in 2011?*
lan W. Heldman, MD, Juan P. Zambrano, MD,
oshua M. Hare, MD
iami, Florida
ell therapy may transform the treatment of acute and
hronic heart disease, with an anticipated impact rivaling
he results of revascularization and reperfusion therapies
eveloped in the last 50 years. Through controversies over
he mechanisms of cell therapy, engraftment, and differen-
iation, the biological and translational (1) studies per-
ormed over the past decade shape the future of this very
xciting new field of cardiovascular medicine (2). The
essons learned in the repair of ischemic and other myocar-
ial diseases will also yield biological insights for the
reatment of other organ systems.
ell Therapy Programs of the 2000s
he basic notion of cell therapy for an acute or chronic
njury was that the correct cell type—presumably a stem or
recursor cell with the ability to engraft into an area of
ardiac injury, and then to differentiate into lost cellular
lements—can be sought and used for cardiac therapeutics.
See page 455
he idea of repopulating the bare patches of a lawn with
ew grass seed seems to have been a vast oversimplification,
s we now understand the variety of pathways by which
xogenous cell administration affect cardiac healing and
emodeling (1,2). The translational application of candidate
ell types has been criticized by some as being applied too
apidly before the cell biology is fully understood (3,4).
onetheless, programs testing various cells in small- and
arge-animal models, followed by proof of principle human
tudies or early phase clinical trials, have moved the field
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Philip H. and Suzi Rudd Cohen Cardiovascular Biology Laboratory in
onor of Joshua M. Hare, MD, Interdisciplinary Stem Cell Institute, University of
iami Miller School of Medicine, Miami, Florida. This work was supported by
ational Heart, Lung, and Blood Institute grants U54-HL081028 (Specialized
enter for Cell Based Therapy), R01-HL084275, and P20 HL101443. Dr. Hare is
upported by RO1s AG025017, HL065455, and HL094849; is on the Steeringp
ommittee for Osiris; and is a consultant for Kardia. All other authors have reported
hey have no relationships to disclose.orward substantially. As is the case in most early fields,
ranslational studies have enabled further controversies as to
hether appropriate strategies are being employed (5), and
ave focused the questions asked by pre-clinical investigators.
mportantly however, translational research has provided an
arly vision of the future for this field, showing clearly what we
now and what we don’t, and providing information on cell
roduct preparation, delivery strategies (6), phenotypes of
esponse to cell therapy (7), the measurement of clinically
elevant and surrogate end points, and the identification of the
linical determinants of patient responsiveness (8).
electing Among Cell Types
he characteristics of the ideal cell type have been articu-
ated by many experts: a cell type should be both quantita-
ively and temporally available, safe to administer, effective
t engraftment, differentiation, and (most importantly) car-
iac repair. Some argue that a source of autologous therapy
s ideal so as to avoid any possibility of rejection, although it
hould be acknowledged that allogeneic cell therapy is also
merging as a strong possibility (8). Practical considerations,
ncluding the cost of therapy, will ultimately bear impor-
antly on the accessibility of a new therapy.
Over the past decade, the translational pipeline has tested
r is in the process of testing: 1) autologous whole bone
arrow (AWBM); 2) skeletal myoblasts; 3) bone-marrow–
erived mesenchymal stem cells (MSCs); 4) MSCs from
ther tissues, and MSC precursors; and 5) a variety of
ardiac stem cell (CSC) preparations.
Pluripotent cells derived from embryonic stem cells (9,10)
r induced pluripotent stem (11) cells are under vigorous
tudy but are several years away from being tested in humans
12). Thus far, AWBM and skeletal myoblasts have yielded
ixed results of surrogate efficacy. AWBM produces small
ut significant increases in ejection fraction, decreases in
nfarct size, and prevents remodeling (13); this cell therapy
ay have clinical benefits out of proportion to the degree of
ardiac functional recovery (14). Bone-marrow–derived
SCs are the most rigorously studied stem cell population
Fig. 1), and this cell type is presently undergoing phase II
esting for myocardial infarction and for heart failure (15).
Cardiac stem cells, discovered in the early part of the
illennium (16), are an exciting and promising potential
lass for cell-based therapies. The best understood is the
ardiac c-kit cell, and it is definitively identified in the
uman heart (17); but other cardiac precursors are described
18,19). Enthusiasm for cardiac stem cells is very high as
hey fulfill most of the criteria anticipated for a cell
herapeutic—they represent an autologous source of cardio-
oietic and vasculogenic precursors that may be readily
vailable. The 2 strategies for preparing cardiac stem cells
arthest along the translational pipeline are to amplify c-kit
SCs from surgical biopsies (usually from the atrial ap-
endage), and to prepare cardiospheres, the topic of the
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January 25, 2011:466–8 Cell Therapy for Heart Diseaseardiospheres are a collection of cells that can be coaxed to
mplify from small pieces of heart tissue (21,22). Cardio-
pheres are composed of a mix of cell types, including 15%
o 20% cardiac precursor cells, with the remainder being
upporting cellular elements with mesenchymal features.
he contributions from the Marbãn group represented by
he current paper (20) and by that of Johnston et al. (23) are
ommendable for their use of rigorous translational large-
nimal models, the employment of delivery systems adapt-
ble to human use, and sophisticated end point phenotyp-
ng. Porcine models can be designed closely to replicate the
linical scenario of reperfused infarction in either acute or
hronic settings (24) and have led to Food and Drug
dministration approval of a phase I trial of the cardio-
phere strategy (25).
The heterogeneity of cellular constituents of the cardio-
phere may prove to be advantageous, as the cell mixture
ay enable the recreation of the cardiopoietic niche (26).
ndeed, this notion is a major conceptual advancement in
he field of cell therapeutics and supports the idea that the
tem cell niche may represent the functional unit of effective
ardiac regeneration (1,26). In this regard, we have recently
hown that bone marrow MSCs work in large part by
ell-cell interactions with endogenous CPCs (1). Optimiz-
ng the process of therapeutic myogenesis may require a
ailored combination of support cells and cardiopoietic
recursors; although comparisons among cell types are at a
ery early stage of investigation, there is a large variety of
herapeutic constructs from which to choose, and the
nsights gleaned from translational models offer major
pportunities to refine and optimize cell therapeutics in the
uture.
here Do We Go From Here?
he optimism for the field of cardiac cell therapy comes in
arge measure from the clear demonstrations of efficacy in
arge-animal models, which have also defined safety param-
Figure 1 MSC Research Publications
Publications on mesenchymal stem cell (MSC) research (blue bars) show substan
with parallel increases in cardiac experimental studies (red bars) and human studters and delivery strategies. If clinical trials replicate even araction of the benefit witnessed in the porcine model, the
edical impact could be substantial. The results of animal
tudies coupled with ongoing early phase clinical trials
uggest entry into the clinic in the next decade. For the next
ave of trials to succeed, investigators must turn their
ttention to comparative studies seeking to define the best
ell, cell combination, or therapeutic schedule. To the extent
hat various cell types produce similar outcomes (a seem-
ngly likely eventuality for clinical outcomes), then consid-
ration of cost and practicality will rise in importance.
There are critically important societal issues to consider as
his field advances. Although cell therapy offers so much
romise and fulfills a major unmet need for patients with
hronic left ventricular dysfunction, public funding for
linical trials in the area is minimal. In addition, intellectual
roperty concerns have almost entirely limited the entry of
ig pharma into the area. Treatments being offered to
aying patients outside the United States are of uncertain
afety and efficacy, yet are being widely sought by patients.
hus, the field finds itself in an awkward, paradoxical
osition—with an enormously promising transformative
herapy looming on the horizon yet with progress being
indered by a relative lack of funding support for transla-
ional research on the one hand and scientific debate on the
ther.
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